Abstract Library

#1823 Effects of Low-Doses Aspirin on Clinical Outcome and Disease Progression in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results of a Multicentric Retrospective Study

Introduction: The chemopreventive effect of aspirin (ASA) have been observed in the setting of colorectal cancer. The impact of aspirin use on clinical outcome of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP NEN) has not been evaluated yet

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cavalcoli F

Authors: Massironi S, Pusceddu S, Cavalcoli F, Zilli A, Tamagno G,

Keywords: NEN, ASA,

#746 Aspirin Delays the Development/Progression of Neuroendocrine Pancreatic Neoplasms and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors

Introduction: So far, there are no chemopreventive strategies for neuroendocrine pancreatic neoplasms.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Fendrich V

Authors: Fendrich V, Manoharan J, Lopez C, Waldmann J, Bartsch D,

Keywords: neuroendocrine pancreatic tumors, aspirin, chemoprevention,

#739 Aspirin Inhibits Cell Viability and mTOR Signalling in Neuroendocrine Tumor Cells

Introduction: Patients with multiple endocrine neoplasia (MEN) type 1 develop pancreatic NETs as well as thymic and bronchus carcinoids. Aspirin has been reported to inhibit mTOR signalling and exhibit antitumoral activity in colorectal cancer cells. So far, no data with aspirin on NETs have been published.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B,

Keywords: neuroendocrine tumor, MEN-1, aspirin, mTOR,